tirzepatide retinopathy The popular #diabetes and weight loss medication #tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic #retinopathy, a leading cause of vision loss, according to Dr. Szilárd Kiss and Tirzepatide Use Linked to Lower

About TRIUMPH-4 and the TRIUMPH clinical trial program TRIUMPH-4 (NCT05931367) is a Phase 3, 68-week, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of retatrutide with placebo in adults with obesity or overweight and knee osteoarthritis

In head-to-head trials, Mounjaro produced ~20% weight loss at 72 weeks vs ~1417% for Wegovy

Outcomes vary: Mild cases may improve with treatment Moderate cases may require long-term management Severe cases can become permanent Some patients develop lifelong GI dysfunction after GLP-1 drug use Early diagnosis significantly improves prognosis

Early detection leads to better patient outcomes

Obesity is more than a mere choice

Call us, or start with the TRT page to see how it works